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Title:  Access, delivery and perceived efficacy of physiotherapy and use of complementary 
and alternative therapies by people with progressive multiple sclerosis in the United 
Kingdom:  an online survey. 
Abstract 
Introduction: All people with progressive MS in the United Kingdom should have access to 
physiotherapy through the National Health Service (NHS). However levels of access and 
delivery are unknown.  Furthermore there is no research on perceived efficacy of 
physiotherapy or the use of complementary and alternative medicine in people with 
progressive MS in the United Kingdom.  
Methods: An online survey was carried out via the UK MS Register.  Inclusion criteria were 
diagnosis of progressive MS, a member of UK MS Register and 18 years or older. The survey 
asked participants regarding access and delivery of physiotherapy; perceived efficacy of 
physiotherapy and interventions received; barriers to accessing physiotherapy and use of 
complementary and alternative medicine.  The following additional data were supplied from 
the UK MS Register: demographics, EQ5D, MSIS-29 physical and psychological sub-scales 
and geographical data. 
Results: Total number of respondents was 1,298 from an identified 2,538 potential 
registrants: 87% could access physiotherapy services, 77% received physiotherapy from the 
NHS and 32% were currently receiving physiotherapy.    The most common interventions 
received were home exercise programme (86%), exercises with a physiotherapist (74%) and 
advice/education (67%).   40% had recently used complementary and alternative medicine.   
2 
 
Perceived efficacy of physiotherapy was high with 70% reporting it to be either ‘beneficial’ 
or ‘very beneficial’.  Main barriers to accessing physiotherapy were mobility, fatigue, 
continence, transport issues, requiring someone to go with them and pain.   
Discussion: Access to physiotherapy was high with most people reporting it as beneficial. 
However 13% reported not have access indicating a gap in accessibility.  Considering some 
of the barriers reported may allow physiotherapy services to address this gap in 
accessibility.  
Keywords 
Progressive Multiple Sclerosis; Physiotherapy; Access; Rehabilitation; Complementary 
Therapies 
ClinicalTrials.gov Identifier: NCT02559765 
Highlights 
 Access to physiotherapy was high at 87% and approximately a third were currently 
receiving physiotherapy  
 Physiotherapy was considered to be beneficial 
 Main barriers to accessing physiotherapy were mobility, fatigue, continence, 
transport issues, needing someone to go with them and pain  
 Thirty eight percent had recently used complementary and alternative therapies 
Abbreviations  
EQ-5D-3L: EQ-5D-3L Health Questionnaire; MS: multiple sclerosis; MSIS-29: Multiple 
Sclerosis Impact Scale version 2; NHS: National Health Service; SD: Standard Deviation  
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1.0 Introduction 
In the United Kingdom there are an estimated 130,000 people living with multiple sclerosis 
(Mackenzie et al., 2014).  Approximately 15% of new cases are diagnosed as primary 
progressive multiple sclerosis, 5% as progressive relapsing multiple sclerosis and 80% as 
relapsing remitting multiple sclerosis.  Around two thirds of those with relapsing remitting 
multiple sclerosis will however, go on to develop secondary progressive multiple sclerosis 
(Miller and Leary, 2007).   Due to the lack of pharmacological treatments for decreasing 
disease activity in those with progressive forms of multiple sclerosis, treatment often 
focuses on symptomatic management and rehabilitation.  To that effect, the International 
Progressive MS Alliance has named rehabilitation of as one of its research priorities for 
progressive multiple sclerosis (Fox et al., 2012). 
For people with progressive multiple sclerosis in the United Kingdom, access to 
physiotherapy via the National Health Service is recommended in guidelines produced by 
the National Institute for Health and Care Excellence (NICE, 2014) and  is part of the 
Healthcare Improvement Scotland neurological clinical standards (Healthcare Improvement 
Scotland, 2009).  However, poor patient satisfaction with access to multiple sclerosis 
physiotherapy services has been reported in several areas of the United Kingdom (Edmonds 
et al., 2007; MacLurg et al., 2005; Markwick et al., 2014).  In the Republic of Ireland, access 
to physiotherapy is reportedly lower in those from rural areas and in people with 
progressive multiple sclerosis compared to people with relapsing remitting multiple sclerosis 
(Lonergan et al., 2015). In addition, high levels of patient satisfaction with physiotherapy 
services have been reported in Sweden and Norway (Normann et al., 2012; Ytterberg et al., 
2008). 
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Despite previous studies highlighting dissatisfaction with physiotherapy services in different 
parts of the United Kingdom the access, and use of physiotherapy services specifically by 
people with progressive multiple sclerosis across the whole of the United Kingdom is 
unknown.  Furthermore, the perceived efficacy of physiotherapy services and barriers to 
accessing them is also unknown. In addition to traditional clinical services, people with 
multiple sclerosis often utilise complementary and alternative therapies in the management 
of their condition and whilst there is literature examining usage across the Nordic countries 
(46-58%) (Skovgaard et al., 2012), the United States of America (58%) (Stoll et al., 2012), 
Germany (67%) (Apel et al., 2006), and Turkey (26%) (Gedizlioglu et al., 2015) there is 
currently no information on the use of complementary and alternative therapies by people 
with progressive multiple sclerosis in the United Kingdom.  
The objectives of this study were to: investigate access, use, delivery and perceived efficacy 
of physiotherapy services and interventions; determine barriers to accessing physiotherapy 
services; and assess use of complementary and alternative therapies by people with 
progressive multiple sclerosis in the United Kingdom. 
2.0 Methods 
2.1 Design and participant recruitment 
In this cross-sectional study an online survey was carried out with participants on the UK MS 
Register.  Registrants sign up voluntarily to the UK MS Register and provide self-reported 
demographic information and diagnosis of multiple sclerosis (Ford et al., 2012).  Registrants 
answer targeted surveys and complete regular self-report measures such as the EQ-5D-3L 
Health Questionnaire (EQ-5D-3L) and the Multiple Sclerosis Impact Scale version 2 (MSIS-29) 
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(described below).  Participant’s data are anonymised and researchers are given secure 
access to the data remotely via the Secure Anonymised Information Linkage gateway (Jones 
et al., 2014).  At the time of this study the UK MS Register had 11,041 members with 4,384 
being active on the Register in the 6 months prior.  In total there were 2,538 registrants who 
reported having a progressive form of multiple sclerosis. 
Participants were eligible for inclusion to this study if they were members of the UK MS 
Register, aged 18 years or older, and had a progressive form of multiple sclerosis.  
Participants were identified by the UK MS Register and emailed informing them of the 
survey. The survey was conducted between August and October 2015.  Informed consent 
was assumed if a participant completed the survey. 
2.2 Data collection  
The survey comprised two sections. The first contained questions related to access, delivery, 
perceived efficacy of physiotherapy and use of complementary and alternative therapies.  
The second was concerned with access to and use of multiple sclerosis specialist and clinical 
services.  Only the first section is described here. The survey took approximately 40 minutes 
to complete and a copy is available upon request. 
The first section asked respondents regarding access to physiotherapy; if they currently 
received physiotherapy for their multiple sclerosis; the referral process; their physiotherapy 
provider; their perceived efficacy of physiotherapy; the frequency and duration of 
appointments; waiting times for appointments; how and where they received 
physiotherapy; and barriers to receiving physiotherapy.  Those who were currently receiving 
physiotherapy were asked what physiotherapy interventions they had received in the prior 
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three months and their perceived efficacy of these. Finally participants were asked which 
complementary and alternative therapies they had used in the prior three months.  As 
acupuncture is delivered as a physiotherapy intervention and as a complementary and 
alternative therapy it was included in both questions. Questions were closed and 
participants were able to select answers from a list of options.  In some questions 
participants were able to choose more than one answer.  Perceived efficacy was rated on a 
five point scale as: ‘very harmful’, ‘harmful’, ‘neither harmful nor beneficial’, ‘beneficial’, 
and ‘very beneficial’.   
2.3 Additional data 
The UK MS Register provided the following additional data: demographics; time since 
diagnosis; Lower Super Output Area codes for participants in England and Wales; Super 
Output Area codes for participants in Scotland (there were no geographical codes available 
for participants in Northern Ireland).  The Lower Super Output Area and Super Output Area 
codes were converted into a classification of rural and urban living using available 
conversion data (Office for National Statistics, 2016; Scottish Office for National Statistics, 
2016).  Urban living was defined as a settlement of 10,000 people or more (Department for 
Communities and Local Govenment, 2006). The results from the most recent EQ-5D-3L and 
MSIS-29 questionnaires completed by participants were also provided. The EQ-5D-3L is a 
self-report measure of quality of life which generates an index ranging from -1 to 1 with a 
higher index indicating a higher quality of life and an index less than zero indicating a quality 
of life worse than death (EuroQol, 1990).  The MSIS-29 version 2 is a self-report measure 
which considers the physical and psychological impact of multiple sclerosis in two sub-scales 
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ranging from 20 to 80 and 7 to 36 respectively.  A higher score indicates a greater impact of 
multiple sclerosis (Hobart et al., 2001). 
2.4 Ethical approval 
Ethical approval was granted by the University of Glasgow’s College of Medical, Veterinary & 
Life Sciences Ethics Committee and the study was peer reviewed by the information 
governance panel of the UK MS Register (South West - Central Bristol Research Ethics 
Committee, Ref: 11/SW/0160). 
2.5 Statistics 
Data were analysed using IBM SPSS v22. All variables were characterised using descriptive 
statistics.  Where appropriate variables were checked for normality, since data were not 
normally distributed Mann-Whitney, Kruskal-Wallis and chi square tests were used as 
appropriate.  Statistical significance was set at p<0.05.  Where results are presented as a 
percentage the total number of responses for that question is reported in brackets. 
3.0 Results  
In total 2538 people were identified from the UK MS register as potential participants and 
were emailed with a link to take part in the survey.  Of those, 1298 completed the survey 
producing a response rate of 51% (Table 1).   
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Table 1.Characteristics of survey responders. 
Number of participants 1298 
Age (years) 59 SD 8 
Time since diagnosis (years) 16 SD 9 
Gender  
  Female  824 
  Male  474 
Country   
  Scotland  131 
  England  1029 
  Wales  104 
  N. Ireland  21 
EQ-5D-3L index 0.49 SD 0.20 
MSIS-29 –psychological sub-
scale 
19.96 SD 6.10 
MSIS-29 – physical sub-scale 55.97 SD 12.64 
Figures where applicable are mean (standard deviation (SD)). Not all participants provided geographical 
information.  The mean time between completion of the survey and the most recent EQ-5D-3L and MSIS-29 
was 39 (SD 120) and 19 (SD 111) days respectively. 
EQ-5D-3L: EQ-5D-3L Health Questionnaire 
 
Of the respondents, 87% (n=1118) had access to physiotherapy and 32% (n=414) were 
currently receiving physiotherapy for their multiple sclerosis (Table 2).  The most common 
methods of referral to physiotherapy were via a multiple sclerosis specialist nurse (43%) and 
self-referral (38%).  Approximately three quarter of participants were receiving their 
physiotherapy from the National Health Service and the remainder from private providers 
or charitable organisations. Seventy one percent received their physiotherapy at home 
(25%) or in a clinical environment or hospital (46%).  The majority of people (80%) reported 
they received physiotherapy on a one to one basis. Ninety percent estimated a waiting time 
of 12 weeks or less after referral and over half of respondents received their physiotherapy 
once per week or more frequently (Table 2).   
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Table 2. Access, referral, and delivery of physiotherapy.  
Question Answers n % 
Can you get physiotherapy if 
you want it? 
n=1291 
yes 1118 87 
no 173 13 
Are you currently receiving 
physiotherapy for your MS? 
n=1287 
yes  414 32 
no 873 68 
Who would you speak to to 
get a physiotherapy 
appointment? 
MS specialist 
doctor/neurologist 
310 27 
GP 366 32 
n=1158 I self-refer 445 38 
 MS specialist nurse 493 43 
 Other  140 12 
 Don’t know  8 1 
Who provides your 
physiotherapy? 
National Health Service 855 77 
Private (self-funded) 207 19 
n=1106 Private (insurance) 21 2 
 Charity 173 16 
 Other 58 5 
Where do you usually receive 
physiotherapy? 
n=461 
In a hospital or clinic 210 46 
At home 116 25 
In a charity centre 110 24 
In a community centre 31 7 
 aOther  63 14 
How many patients are 
normally present at your 
physiotherapy sessions? 
n=457 
1 (individual session) 366 80 
2-4  42 9 
5 or more  81 18 
I receive physiotherapy by 
telephone or online 
5 1 
What is your usual pattern of 
appointments? 
n=451 
Regularly 270 60 
Varies depending on 
symptoms 
181 40 
How long would you expect to 
wait for a physiotherapy 
appointment? 
< 1 week 12 6 
1 or more but less than 2 
weeks 
42 22 
2 or more but less than 4 
weeks 
36 19 
n=192 
4 or more but less than 6 
weeks 
41 21 
 6 or more less than 12 weeks 41 21 
 >12 weeks 20 10 
How often do you usually 
receive physiotherapy? 
n=252 
once or more a week 138 55 
once a fortnight 46 18 
once every 1 to 3 months 53 21 
 twice a year 10 4 
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 once a year or less  5 2 
What is the usual length of 
your physiotherapy sessions? 
<30 minutes 120 26 
30 - 60 minutes 299 65 
n=462 >60 minutes 43 9 
For some questions participants were able to select more than one option. 
MS: multiple sclerosis; n: number of responses. 
aSetting of delivery named as ‘other’ included: care home; private clinic; hydrotherapy pool; charity centre; 
leisure centre/gym. 
 
 
In total 70% of respondents thought that physiotherapy was either ‘beneficial’ or ‘very 
beneficial’ for their multiple sclerosis, 27% were indifferent in their opinion and 3% thought 
that physiotherapy was ‘harmful’ or ‘very harmful’.  The perceived efficacy of physiotherapy 
was higher among those who were currently receiving physiotherapy for their multiple 
sclerosis than those who were not (p<0.001) (Figure 1). Only eight of the 31 participants 
with a negative opinion of physiotherapy had actually received a physiotherapy intervention 
in the prior three months (independent exercise (n=4), exercise with a physiotherapist (n=2) 
and advice/education (n=2)). 
Figure 1. Perceived efficacy of physiotherapy. 
 
0
10
20
30
40
50
very
beneficial
beneficial neither
harmful
nor
beneficial
harmful very
harmful
P
e
rc
e
n
ta
ge
 o
f 
re
sp
o
n
d
e
n
ts
Perceived efficacy
All respondents
Currently receiving
physiotherapy
Not receiving
physiotherapy
11 
 
The most commonly received physiotherapy interventions were; home exercise programme 
(86%); exercises with a physiotherapist (74%) and advice or education (67%). The perceived 
efficacy of all interventions was predominantly ‘beneficial’ or ‘very beneficial’.  People who 
received acupuncture and transcutaneous electrical nerve stimulation were less positive 
about the efficacy of these interventions although the opinion of these interventions was 
still predominantly positive (Table 3). 
Table 3. Perceived efficacy of physiotherapy interventions received by respondents.   
Intervention 
% of 
total 
n 
very 
harmful harmful  
neither 
harmful nor 
beneficial  beneficial 
very 
beneficial  
Home exercise 
programme 
86 0 1 12 58 28 
Exercise with 
physiotherapist 
74 <1 <1 6 39 54 
Advice/Education 67 0 <1 8 50 41 
FES 25 0 3 21 29 47 
Standing frame 18 0 3 8 53 37 
Acupuncture 10 2 5 36 31 26 
TENS 7 3 10 34 34 17 
Othera 5 - - - - - 
Total respondents n=452.  All values are percentages.  Participants were able to choose more than one option. 
n: number of respondents; FES: functional electrical stimulation; TENS: transcutaneous electrical nerve 
stimulation. 
ainterventions named as ‘other’ all had n<10 and included: hand physiotherapy, women’s health 
physiotherapy, medication, orthotics, manual therapies, whole body vibration, and walking aid prescription. 
Eighty nine percent of those receiving their physiotherapy from non- National Health Service 
providers had an expected waiting time of four weeks or less for a physiotherapy 
appointment compared to 39% of those receiving National Health Service physiotherapy 
(Table 4).  Statistical analysis was not possible due to the small proportions of participants 
who felt that physiotherapy would be harmful to them.   
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Table 4. Expected waiting times by source of physiotherapy. 
Physiotherapy 
provider 
 Expected waiting time (weeks) 
  <1 1 - 2 2- 4 4- 6 6 – 12 >12 
NHS n=133 2% 22% 15% 28% 23% 10% 
Non-NHS n= 26 27% 39% 23% 0% 12% 0% 
Both n=27 7% 11% 33% 11% 19% 19% 
NHS: National Health Service; n: number of responses. 
 
The most common barriers to receiving physiotherapy were described as: mobility (40%), 
fatigue (39%), continence issues (21%), transport issues (21%), and needing someone to go 
with them (21%).  Participants were also asked to identify the three greatest barriers to 
receiving physiotherapy and pain was named as a barrier in addition to those listed above.   
Twenty three percent of respondents reported that there were no barriers to them 
accessing physiotherapy (Supplementary table 1). 
Those who had access to physiotherapy rated their quality of life, as measured by the  EQ-
5D-3L  index, to be significantly better compared to those who did not have access 
(p=0.048)  (Table 5).  Those who were currently receiving physiotherapy for their multiple 
sclerosis had a significantly lower psychological impact of multiple sclerosis, as measured by 
the MSIS-29 psychological sub-scale, compared to those who were not receiving 
physiotherapy (p=0.019).  However, those who had access and those who were currently 
receiving physiotherapy were younger and had a shorter time since diagnosis (all p<0.05) 
than those who did not have access and were not receiving physiotherapy. There were no 
other statistically significant differences between the EQ-5D-3L index and MSIS-29 sub scale 
scores and physiotherapy provision (Table 5).   
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Table 5. Associations between access to and receiving physiotherapy and respondent 
demographics. 
  Access to physiotherapy  Receiving physiotherapy  
Variable  n median p n median p 
EQ-5D-3L  
index 
Yes 1089 0.57 0.048* 401 0.57 0.778 
  No 167 0.50  852 0.57  
MSIS-29 phys Yes 1113 56 0.199 411 57 0.83 
  No 173 58  871 57  
MSIS-29 psych Yes 1102 19 0.435 403 19 0.019a 
  No 170 20  865 20  
Time since  Yes 1082 14.5 0.034* 680 14.0 0.009a 
diagnosis No 165 17.0  158 17.0  
Age Yes 1118 59 <0.001* 704 59 <0.001a 
 No 173 61  166 61  
Urban dwelling Yes 746 - 0.418 273 - 0.913 
 No 110 -  581 -  
Rural dwelling Yes 330 -  125 -  
 No 57 -  260 -  
n: number of responses; EQ-5D-3L: EQ-5D-3L Health Questionnaire; MSIS-29 – phys: Multiple Sclerosis Impact 
Scale physical sub-scale; MSIS-29 – psych: Multiple Sclerosis Impact Scale psychological sub-scale; PPMS: 
Primary Progressive Multiple Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis.  
aStatistically significant from Mann-Whitney test. 
 
In total 38% (n=462) of respondents had used complementary and alternative therapies for 
their multiple sclerosis in the prior three months (Table 6).  The three most commonly used 
complementary and alternative therapies were massage (17%), reflexology (12%) and 
relaxation or meditation (10%). 
 
 
 
 
 
 
14 
 
Table 6. Complementary and alternative therapies used in the prior three months. 
Complementary and alternative 
medicine n % 
Massage 207 17 
Reflexology 146 12 
Relaxation or meditation 123 10 
Hyperbaric oxygen therapy 85 7 
Acupuncture or acupressure 72 6 
Osteopathy or chiropractic 58 5 
Homeopathy or herbal medicine 40 3 
Reiki 33 3 
Aromatherapy 32 3 
Magnet field therapy 9 <1 
The Alexander technique 7 <1 
Other   29 2 
None 747 62 
Total responders n=1209, participants were able to choose more than one option. 
Complementary and alternative medicines named as ‘other’ (all n<7): action potential stimulation; bee venom; 
Bowen technique; ‘circulation booster’; craniosacral therapy; diet management; low dose Naltrexone; ‘muscle 
activation therapy’; SCENAR device; and supplements. 
 
4.0 Discussion  
This was the largest United Kingdom based survey of solely people with progressive multiple 
sclerosis and the first to explore access, delivery and efficacy of physiotherapy services in 
this patient group in the United Kingdom.  Access to physiotherapy in this sample was high 
(87%), with approximately one third currently receiving physiotherapy for their multiple 
sclerosis.  A recent survey of people with all types of multiple sclerosis in the United 
Kingdom found 17% of respondents did not have access (MS Society, 2016b).  This is similar 
to the present results in which 13% of respondents did not have access to physiotherapy 
services. In addition the MS Society report suggested 32% of people with multiple sclerosis 
were receiving physiotherapy from non-National Health Service providers, compared to 42% 
in the present study. Although the results are similar, the slight discrepancies may be 
explained by differences in multiple sclerosis sub-type. The present study focussed on 
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people with progressive forms of multiple sclerosis who may have a greater need of 
physiotherapy.   
The most common setting of physiotherapy delivery was in a hospital or clinical 
environment (46%).  This is in line with another report from the MS Society which, whilst 
calling for more community based care, found that the majority of multiple sclerosis care is 
delivered in the hospital setting (MS Society, 2016a). 
In the United Kingdom, target waiting times for therapies, not specifically physiotherapy, 
range from 14-21 weeks (JJ Consulting, 2011).  Overall 90% of this sample reported an 
expected waiting time for a physiotherapy appointment of 12 weeks or less.  However, 
expected waiting times varied depending on service provider: 89% of those receiving their 
physiotherapy only from non-National Health Service providers reported an expected 
waiting time of just four weeks or less compared to 39% of those receiving their 
physiotherapy from the National Health Service.  The overall result (90% waiting  12 weeks 
or less to see a physiotherapist) is different from a United Kingdom wide report by the 
Chartered Society of Physiotherapy which reported that 83% of neurology outpatients were 
seen by a Neurology physiotherapist in eight weeks or less (JJ Consulting, 2011).  Differences 
may be due to this sample being made up solely of people with progressive multiple 
sclerosis and the question asked was in regard to expected waiting times. 
Respondents were generally positive in their opinion of physiotherapy with 70% of 
respondents reporting it to be either ‘beneficial’ or ‘very beneficial’ to them. Indeed only 3% 
thought that physiotherapy had a negative effect.  The most commonly received 
interventions were also perceived to be the most beneficial.  All of the physiotherapy 
interventions which participants received, apart from acupuncture, have evidence to 
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support their effectiveness in people with progressive multiple sclerosis (Campbell et al., 
2015).  
The three most common interventions received, home exercise programme, exercise with a 
physiotherapist and advice, were also reported as being the most beneficial. Our  previous 
systematic review found strong evidence to support the use of exercise to improve mobility 
and function in multiple sclerosis (Campbell et al., 2015). In addition patient education has 
been found to increase disease knowledge in patients with multiple sclerosis (Kopke et al., 
2014).  One intervention, transcutaneous electrical nerve stimulation, was generally 
reported to be beneficial although 13% reported it to be potentially harmful. This negative 
opinion is in contrast with two systematic reviews which concluded that transcutaneous 
electrical nerve stimulation was both safe and effective for treating spasticity (Fernandez-
Tenorio et al., 2016) and pain (Sawant et al., 2015) in multiple sclerosis although the type of 
multiple sclerosis may have an impact upon efficacy (Sawant et al., 2015). 
The most commonly reported and greatest barriers to accessing physiotherapy can be 
categorised as logistical (transport issues, needing someone to go with them) and 
symptomatic (mobility, fatigue, continence and pain).  A study by Asano et al. found similar 
barriers to participating in exercise in people with multiple sclerosis (Asano et al., 2013).  An 
increase in care close to home could address the logistical barriers and potentially reduce 
the impact of the symptomatic barriers.  Indeed the recent report from the UK MS Society 
called for more community based care (MS Society, 2016a).  Simple solutions such as the 
timing of appointments to address fatigue and ensuring adequate and clearly signposted 
toilet facilities to address concerns with continence may also be considered. 
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Having access to physiotherapy was associated with better quality of life and currently 
receiving physiotherapy was associated with less of a psychological impact of multiple 
sclerosis but not physical impact.  As this was a cross-sectional study it was not possible to 
draw causality between these variables.   Having access to, or receiving, physiotherapy was 
not associated with urban or rural dwelling.  This is in contrast to research conducted in the 
Republic of Ireland which found a lack of access to physiotherapy in people with multiple 
sclerosis from rural areas (MacLurg et al., 2005).  A greater proportion of Ireland’s 
population does however live rurally (37% compared to 18% in the United Kingdom) which 
may account for the differences in results (World Data Bank, 2016). 
Thirty eight percent of this sample had used a complementary and alternative therapy in the 
past three months for their multiple sclerosis.  This result was lower than complementary 
and alternative therapies use in Germany (67%) (Apel et al., 2006), the United States of 
America (58%) (Stoll et al., 2012) and the Nordic countries (46-58%) (Skovgaard et al., 2012) 
but higher than complementary and alternative therapies use in Turkey (26%) (Gedizlioglu 
et al., 2015).  The majority of the participants in the studies which reported higher 
complementary and alternative therapies usage had relapsing remitting multiple sclerosis 
and were mildly or moderately affected.  In addition, a study in Germany found that the 
majority of complementary and alternative therapies use by people with multiple sclerosis 
happens in the early stages of the disease as initially they explore all avenues (Kochs et al., 
2014).  As the participants in this sample had a mean time since diagnosis of 16 years this 
may explain why complementary and alternative therapies use was lower that most of 
previous research where, when reported, time since diagnosis was from seven to nine years 
(Apel et al., 2006; Gedizlioglu et al., 2015). 
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4.1 Limitations 
This study had a number of limitations.  The cross-sectional design does not allow for 
causality to be drawn between associations.  There was the potential for sample bias as 
those who engage with the UK MS Register may be more likely to seek out and engage with 
services.  Furthermore, the diagnosis of multiple sclerosis type was self-reported, however 
in future the UK MS Register intends to be linked with clinical data from the National Health 
Service. A lack of geographical data from those in Northern Ireland meant that comparison 
of rural and urban dwelling in this part of the country was not possible limiting the 
nationwide applicability of the result. Due to the programming of the survey some 
participants were able to complete it without answering all of the questions and due to the 
low number of participants who completed the question regarding expected time to wait 
for an appointment this meant only 192 participants answered every single question.  
Subsequently percentages were calculated from the number of respondents to each 
question. Finally, the number of people who had access to physiotherapy was 6.5 times 
greater than the number of people who did not, as such results comparing these two groups 
should be interpreted with some caution. 
5.0 Conclusion 
This was the first study to focus on physiotherapy access and use by people with progressive 
multiple sclerosis in the United Kingdom and as such provides a unique insight.  Overall this 
study has shown that access and perceived efficacy of physiotherapy is high in the United 
Kingdom amongst people with progressive multiple sclerosis.   However, 13% did not have 
access to physiotherapy which indicates a gap in service accessibility. It is recommended 
that health care providers improve and increase accessibility to physiotherapy for people 
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with progressive multiple sclerosis by considering the barriers highlighted, for example 
providing care closer to home.  
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